Navigation Links
Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
Date:1/8/2014

SAN FRANCISCO, Jan. 8, 2014 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 32nd Annual J.P. Morgan Healthcare Conference in San Francisco at the Westin St. Francis Hotel on Tuesday, January 14, 2014 at 10:00 a.m. Pacific time.

The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website: http://www.nektar.com. This Webcast will be available for replay until February 18, 2014.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms.  Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate, which has been filed for regulatory approvals in the U.S., Europe and Canada as a once- daily, oral tablet for the treatment of opioid-induced constipation.  This agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of naloxegol and an opioid.  NKTR-181, a novel mu-opioid analgesic candidate for chronic pain conditions, has completed Phase 2 development in osteoarthritis patients with chronic knee pain.  NKTR-192, a novel mu-opioid analgesic in development to treat acute pain is in Phase 1 clinical development.  In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study (the BEACON study)
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
2. Nektar to Announce Financial Results for the Third Quarter of 2013 on Thursday, November 7, 2013, After Close of U.S.-Based Financial Markets
3. Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
4. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2013
5. Nektar to Announce Financial Results for the Second Quarter of 2013 on Thursday, August 8, 2013, After Close of U.S.-Based Financial Markets
6. Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
7. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
8. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
9. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
10. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the Jefferies 2013 Global Healthcare Conference in New York City
11. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... -- Market Research Report on Global and Chinese ... and in-depth market survey on Global and ... firstly reviews the basic information of X-Ray Crystallography ... The report then explores global and China,s top ... specification, capacity, Production value, and market share etc. ...
(Date:8/29/2014)... ANGELES , Aug. 29, 2014  Chuma ... both financing alternatives and turnkey support services for ... announce that FINRA processed and approved the Company,s ... 29, 2014, CannaMed Corporation will be known as ... change was accomplished through a merger with the ...
(Date:8/29/2014)... HILL, N.C. , Aug. 29, 2014 ... Leaders (KOLs) can be the difference between a product,s ... to effectively map and stratify KOL targets – and ... build the type of strong relationships upon which successful ... research, savvy pharma companies have identified internal inconsistencies in ...
Breaking Medicine Technology:X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5CannaMed Announces Name Change and Trading Symbol Change 2CannaMed Announces Name Change and Trading Symbol Change 3Implementing a Strategic Thought Leader Management & Engagement System 2
... Biosciences announced,today, the initiation of a Phase 2 ... management of acute infectious,mononucleosis. Currently, there are no ... or any other disease caused by,the Epstein-Barr virus ... of anti-viral activity,including inhibition of viral replication of ...
... Dec. 6 Rigel,Pharmaceuticals, Inc. (Nasdaq: RIGL ) ... ), has begun a Phase 1 clinical trial of ... R343,for the treatment of allergic asthma. R343 is the ... terms of the companies, 2005 collaboration agreement, Rigel,will receive ...
Cached Medicine Technology:Epiphany Biosciences Reports Initiation of Phase 2 Study of Valomaciclovir for the Treatment of Acute Infectious Mononucleosis 2Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer 2Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer 3
(Date:8/30/2014)... PA (PRWEB) August 30, 2014 "My ... sleep knowing that, at any moment, her fever might ... order to keep me well aware of how she ... developed the TEMP ALARM to continuously monitor a child's ... develops a fever. This ensures that prompt medical care ...
(Date:8/30/2014)... August 30, 2014 Serving contented clients ... India, Profit By Outsourcing is now offering discount ... The company gives emphasize on putting forward the best ... to clients. Their dedicated team of professionals and web ... They can handle even the critical issues of web ...
(Date:8/30/2014)... Bringing forth the great opportunities, India's #1 ... Day discount on all SEO services. While working with ... related to internet marketing. Their dedicated team of professionals ... have a deep understanding for their specialization. This further ... since the inception, they have worked with over 5000 ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 The ... mesh lawsuits ( http://www.injurybeacon.com/transvaginal-mesh/ ) filed against Boston ... sever four cases selected for one of the ... on August 18, 2014, U.S. District Judge Joseph ... Virginia disagrees with Boston Scientific’s contention that a ...
(Date:8/30/2014)... "I had a handicapped friend who could not ... inventor from Wetumpka, Ala. "In order to help her be ... I came up with a way for her to use ... for the patent-pending Deezers to allow crutches to be used ... crutches, walkers, or canes at the beach. The device reduces ...
Breaking Medicine News(10 mins):Health News:Profit By Outsourcing Offering Discount for Labor Day on all Web Development Services 2Health News:Profit By Search Announces Labor Day Discount on SEO Services 2Health News:Transvaginal Mesh Lawsuit News: Federal Judge Refuses Boston Scientific Request for Separate Trials in Four Bellwether Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: Federal Judge Refuses Boston Scientific Request for Separate Trials in Four Bellwether Cases, Bernstein Liebhard LLP Reports 3
... As world health leaders work vigorously to consider ... Consumer Specialty Products Association says taking simple precautions can ... something everyone should take seriously," said Chris Cathcart, CSPA ... to keep themselves and their families healthy now and ...
... A West Australian research team has made the world-first ... Liar, that leads other molecules into the nucleus of ... prostate, breast and colon cancers as well as leukemia. ... Australian Institute for Medical Research (WAIMR) led by Associate ...
... Ashley Koff R.D. helps Americans find healthier choices--BEVERLY HILLS, ... proud to announce Ashley Koff Approved (AKA), the unbiased ... several years of hearing her clients, medical colleagues, and ... recognized as a trusted source in the world of ...
... Spiderman Mulholland, one of the country,s leading forensic ... mold, is conducting investigations and working with environmental ... issues that have impacted homes and buildings in ... to date points to sulfur emissions that corrode ...
... reports show Google lobbied on the electronic medical ... contradicting the Internet giant,s earlier claims that Consumer ... false."Google,s report shows a total expenditure of $880,000 ... health-related initiatives; issues relating to online personal health ...
... system to reduce , workload, improve patient care, minimize ... Vocantas Inc., a developer of automated telephone outreach solutions, ... The Ottawa Hospital to manage patients in its Thrombosis ... in the Canadian Medical Association Journal shows that CallAssure ...
Cached Medicine News:Health News:Swine Influenza Outbreak - How to Stay Healthy 2Health News:WA discovery a key to blood cell development 2Health News:Introducing 'Ashley Koff Approved' (AKA): the Stamp of Nutrition for Optimal Health 2Health News:Forensic Expert Investigating Chinese Drywall Issue 2Health News:Consumer Watchdog: U.S. Senate Records Reveal Google Inc. Lobbying Campaign on Personal Medical Records Law Despite Internet Giant's Denials 2Health News:Consumer Watchdog: U.S. Senate Records Reveal Google Inc. Lobbying Campaign on Personal Medical Records Law Despite Internet Giant's Denials 3Health News:Award-winning partnership proves Vocantas CallAssure effective tool for chronic disease management 2Health News:Award-winning partnership proves Vocantas CallAssure effective tool for chronic disease management 3Health News:Award-winning partnership proves Vocantas CallAssure effective tool for chronic disease management 4
... Ergonomic Design for Unparalleled Comfort Pick ... Notice the balance. Notice the trigger and ejector ... Thats because our pipettors are ergonomically designed to ... hours of pipetting. Productivity In The Palm ...
... Ergonomic Design for Unparalleled Comfort ... it. Notice the balance. Notice the trigger and ... left-handed. Thats because our pipettors are ergonomically designed ... long hours of pipetting. Productivity In The ...
... The Finnpipette BioControl multichannel ... features as the single ... handle fits all seven ... channel tip cone modules. ...
... , The new Finnpipette Novus is so user-friendly that ... few minutes. With the intuitive instantly familiar menu and ... functions you need quickly and easily. The large, clear ... names of all functions. The easily accessible two ...
Medicine Products: